Clinical Trials Browser

fluoromisonidazole × Gastrointestinal × Clear all

NCT05250895 2025-03-13

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

Phase EARLY_PHASE1 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT02695628 2024-01-31

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

Phase 2 Completed

5 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT03303469 2021-02-21

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Phase 2 Terminated

3 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02471313 2019-04-23

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

Phase 2 Completed

3 enrolled 5 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01254591 2013-08-26

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

Phase NA Unknown

BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lung Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Colorectal Neoplasms

NCT01213030 2012-09-25

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Phase 1/2 Completed

GastrointestinalHead & NeckThoracic

Hypoxia, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms